3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
61
Lymphoid
32
Myeloid
8
Sarcoma
4
Plasma cell
4
Classical hematology
2
Other neoplasm
1
Dermatologic
1
CNS
1
Conditions
Lymphoma
5
Central Nervous System Neoplasms
4
Neuroblastoma
2
Meningeal Carcinomatosis
2
Brain Neoplasms
2
Vasculitis, Central Nervous System
1
Thrombocytopenia
1
Stiff-Person Syndrome
1
Rhabdoid Tumor
1
Recurrence
1
Rasmussen subacute encephalitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
1
Opsoclonus-Myoclonus Syndrome
1
Neurotoxicity Syndromes
1
Neuromyelitis Optica
1
Neurofibromatosis 1
1
Myasthenia Gravis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Lambert-Eaton Myasthenic Syndrome
1
Intraocular Lymphoma
1
HIV Infections
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Autoimmune Diseases of the Nervous System
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Drug Therapy
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
cemiplimab
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Cytarabine
×
CNS
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled